For the latest COVID information Click Here.
Updated December 2024
Anifrolumab is a type of medicine called a biological disease-modifying antirheumatic drug (bDMARD). It is used to treat systemic lupus erythematosus (SLE).
Type 1 interferons (INF) are proteins that help your body fight viruses. In SLE, the body produces too much INF, which can cause problems with your skin, joints, and other organs.
By impacting on the way these INF proteins work, anifrolumab reduces inflammation and lessens the symptoms associated with SLE.
You may notice improvements in skin rashes and joint pain, stiffness, and swelling within the first 12 weeks of starting. Your doctor may be able to gradually reduce the dose of steroids if you are currently taking this medicine.
Keep taking your treatment unless your doctor tells you to stop or if you experience any side effects (see Side effects). If you stop anifrolumab for any reason you must contact your doctor.
Regular check-ups with your rheumatologist and blood tests will be required to monitor your condition and how well the treatment is working. If you have an active infection, see your doctor to have this treated as soon as possible.
Anifrolumab is given through a ‘drip’ (intravenous infusion) every 4 weeks, but it is possible your rheumatologist may change this over time.
Anifrolumab can be taken with other lupus medicines. Anifrolumab is not used with other bDMARDs.
In clinical trials, anifrolumab has been studied for several years. Currently, there is no known time limit for how long it can be used if it continues to treat lupus effectively and does not cause harmful side effects.
You might experience side effects with your treatment. Contact your doctor if you have any concerns about possible side effects. Many side effects will go away when anifrolumab is stopped.
Most common possible side effects
The most common side effects with anifrolumab include:
Less common or rare possible side effects
The serious side effects with anifrolumab include:
Infections
Anifrolumab will not be given if you have an active infection. It is usual to be screened for chronic infections before giving anifrolumab, which may include:
Vaccines
Cancer risk
Use with other medications
Use with alcohol
Use in pregnancy and when breastfeeding